Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUS 131

Next Previous
X
Search
Drug Profile

AUS 131

Alternative Names: AUS-131; S-equol

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ausio Pharmaceuticals
  • Developer Ausio Pharmaceuticals; University of Kansas Medical Center; University of Texas Health Science Center at San Antonio
  • Class Antidementias; Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Benign prostatic hyperplasia; Vasomotor symptoms
  • Phase I/II Alzheimer's disease
  • No development reported Osteoporosis; Triple negative breast cancer

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-0 development in Breast-cancer(First-line therapy) in USA (PO, Tablet)
  • 09 Jun 2020 AUS 131 is still in phase-0 development in Triple negative Breast-cancer(First-line therapy) in USA (PO, Tablet) (NCT02352025)
  • 29 May 2020 Efficacy and adverse events data from a phase 0 trial in Breast cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top